Insitro is a next generation pharmaceutical company utilizing machine learning (“ML”) technologies to accelerate and streamline the process of new drug discovery.

Insitro’s platform is driven primarily by computational biology technologies supported by traditional discovery approaches:

(i) The platform bridges life sciences, engineering and data science to construct and reiterate on biological models at high fidelity and throughput; and
(ii) The ML-first approach gives Insitro the potential to reduce the cost of developing and the time required to develop new drugs by using a tight, closed loop integration of in-silico and in-vitro methods.

Insitro uses high-quality data that has already been collected and creates its own datasets using high throughput approaches.